Background: The PREVEND IT trial reported on a high cardiovascular (CV) event rate in subjects with a baseline urinary albumin excretion (UAE) rate of ≥50 mg/24 h. Here, we report on the observed 10-year CV outcome of this population and compare this with the predicted Framingham Risk Score (FRS). In addition, we evaluated the effect of four years of fosinopril treatment on this relation. Methods and results: From the PREVEND IT cohort, 833 subjects without history of CV disease, randomized to fosinopril (N = 412) or placebo (N = 421), were studied. The primary endpoint included CV mortality and adjudicated hospitalization for CV disease during a 10-year follow-up period. Mean age was 51 ± 12 years and 65% were males, while prevalence of diabetes (2.6%) and use of CV drugs (3.5%) was low. Subjects were categorized to high UAE (≥50 mg/24 h) or low UAE (b50 mg/24 h). After 10 years of follow-up, the event rate in the high UAE group was almost twice as high as predicted by the FRS (29.5% vs. 17.2%). Treatment for four years with fosinopril reduced the event rate to comparable levels of that predicted by FRS. The addition of UAE ≥50 mg/24 h to the FRS improved the Integrated Discrimination Improvement (P = 0.033) and increased the area under the curve by 0.54% (P = 0.024).
Introduction
Cardiovascular (CV) disease may be predicted by a variety of clinical, biochemical, and surrogate risk factors. Of these, endothelial dysfunction has also been linked to the development of atherogenesis [1, 2] . Increased levels of urinary albumin excretion (UAE) do not only provide an indication of early renal dysfunction, but functions also as a marker of endothelial dysfunction [3] . Many trials have reported on a high prevalence of elevated UAE not only in high risk subjects suffering from diabetes [4, 5] , renal failure [6] , or heart failure [7, 8] , but also in subjects from the general population [9] . An increased UAE was in every cohort associated with worse outcome. Recently, the Prevention of REnal and Vascular ENd-stage Disease Intervention Trial (PREVEND IT) confirmed these results and reported on a CV event rate of almost 30% in subjects with a baseline UAE ≥ 50 mg/24 h after 10 years of follow-up [10] . Some have proposed that UAE may be a useful surrogate marker for CV disease. It is unclear whether conventional CV risk prediction models, like the Framingham Risk Score (FRS) can be used in a population with albuminuria [11, 12] . In addition, it remains unclear whether the addition of UAE could significantly improve prognostic performance of the FRS. In this analysis, we retrospectively investigate the quality of the CV risk estimations by the FRS by comparing it to the observed outcome in PREVEND IT.
Material and methods

Study population
The study was performed using data of the PREVEND IT study, which has been described elsewhere [10, 13] . Briefly, the aim of PREVEND IT was to assess the value of albuminuria as an indicator of increased CV risk in the general population. The key entry criteria of PREVEND IT were persistent microalbuminuria (one urinary albumin concentration ≥ 10 mg/L in an early morning spot urine test and at least one 15 to 300 mg/24 h in two 24 h urine samples), absence of antihypertensive and lipid-lowering medication, a blood pressure of b160/100 mm Hg and a total cholesterol of b 8.0 mmol/L or b5.0 mmol/L in the case of previous myocardial infarction. From April 1998 to June 1999, 864 subjects were included in the PREVEND IT and were randomized to 20 mg fosinopril or matching placebo for the duration of four years (referred to as "active trial period"). At the end of this four year period, all subjects were taken off study medication and returned to the care of their general practitioners. Follow-up time was extended for an additional 6.0 years after the active trial period was ended, resulting in a total follow-up time of 10.0 years. To evaluate the FRS in our sample, we excluded subjects in which the variables of FRS were missing (N = 2, both missing values of HDL-cholesterol) or subjects with a history of CV disease (N = 29). Finally, a total of 833 subjects were eligible for the current analysis. An independent data and safety monitoring committee regularly monitored the progress of PREVEND IT during the entire follow-up period. The study was approved by the institutional medical ethics committee and conducted in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. Informed consent was obtained from all subjects before randomization.
Endpoint collection and follow-up
The composite primary endpoint is the combined incidence of CV mortality and hospitalization for CV morbidity. CV morbidity was defined as hospitalization for documented nonfatal myocardial infarction or myocardial ischemia, heart failure, peripheral artery disease, and/or cerebrovascular accident. These endpoints are the same as for the FRS for general CV disease [14] . Follow-up for all surviving subjects after the active trial was collected via personal communication and electronic hospital files. Data on mortality were retrieved from the municipal register. Cause of death was obtained through the Dutch Central Bureau of Statistics and was coded according to the 10th revision of the International Classification of Diseases. Follow-up on hospitalization for CV morbidity was derived from records held by PRISMANT, the Dutch national registry of hospital discharge diagnoses [15] . In addition, personal communication was used to obtain data from subjects lost to follow-up. The date of admission was used as the date of the event. Details of each CV event were obtained from the treating physician. The independent end point committee of the active trial period reviewed all end points and the members had no knowledge of the subject's treatment assignments.
Measurements
At trial follow-up visits, various clinical and biochemical measurements were performed and two 24-hour urine collections were obtained. Systolic and diastolic blood pressures were calculated as the mean of the last two of ten consecutive measurements, using an automatic Dinamap XL model 9300 series device (Johnson & Johnson Medical Inc.). Serum creatinine, plasma cholesterol and glucose were determined in one laboratory by Kodak Ektachem dry chemistry (Eastman Kodak, Rochester, NY, USA), using an automated enzymatic method. The intra-and interassay variation coefficient of serum creatinine were respectively 0.9% and 1.1%. Serum triglycerides were measured enzymatically. A commercially available assay system was used to assess high-density lipoprotein (HDL) cholesterol (Abbott Inc., Abbott Park, IL, USA). Urinary albumin concentrations were determined by nephelometry with a threshold of 2.3 mg/L and intra-assay and interassay coefficients of variation of less than 2.2% and 2.6%, respectively (Dade Behring Diagnostic). 10-year risk for CV events according to the FRS was calculated as described by D'Agostino [14] and divided into three risk categories: low (b10%), intermediate (10-20%) and high (N 20%), as recommended by Wilson [16] . UAE was categorized by low (b50 mg/24 h) vs. high (≥ 50 mg/24 h), according to the quintiles used in PREVEND IT [10, 13] .
Statistical methods
Baseline continuous data are reported as mean (standard deviation) for normal data. Normality of variables was assessed by standard numerical methods, using skewness/kurtosis tests. UAE and triglycerides showed a log-linear functional shape with the response variable and were transformed to a 2-log scale and reported as median (interquartile range). This means that risk estimates should be interpreted as the relative risk of values were doubled (e.g. 1 to 2 mg/L or 10 to 20 mg/24 h). Times to first occurrence of outcomes are presented as Kaplan-Meier estimates, and statistical differences between placebo and active treatments were analyzed by log-rank testing. To assess the additive value of UAE over the FRS, we evaluated the Integrated Discrimination Improvement (IDI) and Net Reclassification Improvement (NRI) indices for UAE (both as a continuous variable as well as dichotomized to high vs. low, using a cut-off of 50 mg/24 h) according to FRS. All reported probability values are two-tailed and P b 0.05 was considered as the nominal level of statistical significance. All analyses were performed using StataIC (version 11.0 software for Windows).
Results
Baseline characteristics of subjects divided by low (b50 mg/24 h) vs. high UAE (≥50 mg/24 h) are summarized in Table 1 . These characteristics show a middle-aged population with a low prevalence of conventional CV risk factors, exemplified e.g. by a low prevalence of diabetes mellitus (4.0%), and little use of CV drugs (3.5%). The subjects in the high UAE group were at baseline older and had higher levels of systolic and diastolic blood pressures and a higher resting heart rate. Also, levels of glucose, triglycerides and serum creatinine were slightly increased in the high UAE group. Baseline median FRS was 12.7% and was different between UAE groups, namely 11.9% (IQR 5.2-23.9) and 17.1% (IQR 7.8-30.7) for the low UAE and the high UAE group (P = 0.001), respectively. Mean follow-up was 10.0 years (range 9.8 to 10.3) from start of the active trial until 1 January 2009.
At baseline, median UAE was 19 mg/24 h (IQR 15-29) in the low UAE group and 77 mg/24 h (IQR 59-115) for the high UAE group (P b 0.001). The following changes, during the entire follow-up period are depicted in Fig. 1 . The low and high groups of UAE are divided by treatment group. In the low UAE group, 4 years of treatment with fosinopril during the active trial resulted in a decrease in median UAE from 20 mg/24 h to 15 mg/24 h (P = 0.003 compared to baseline). In the high UAE group, fosinopril treatment decreased UAE to 55 mg/24 h (P = 0.003 compared to baseline). Three months after cessation of fosinopril, median UAE increased in both groups and remained stable during further follow-up. UAE was unaffected by placebo during the entire follow-up period.
During the entire follow-up, the primary endpoint occurred in 119 subjects. The event rate in the high UAE group was significantly higher, compared to the low UAE group (22.0% vs. 12.3%, respectively, P = 0.001). Treatment with fosinopril lowered the event rate in the high UAE group to the same height as subjects with low UAE levels at start (15.6% vs. 12.3%, respectively, P = 0.436).
The observed ten-year event rate for both the low UAE group as well as the high UAE group is plotted against the FRS-predicted risk, in Fig. 2A and B. In subjects with UAE b50 mg/24 h, the observed event rate is identical to the FRS-predicted event rate. There was no effect of fosinopril on the observed event rate in the low UAE group. In contrast, the 10 years event rate of subjects in the group UAE ≥ 50 mg/24 h is significantly underestimated compared to the predicted 10 years FRS-predicted risk. The event rate almostdoubled, from 17.2% (FRSpredicted) to 29.5 (observed). Treatment for 4 years with fosinopril during the active trial period significantly reduced the observed CV risk and outcome compared to placebo, and normalized the actual CV risk to the FRS-predicted CV risk level ( Table 2 ).
The Integrated Discrimination Improvement (IDI) index for including UAE to the FRS was significant, P = 0.033 (outcome variable: primary endpoint). The area under the curve for the FRS in our sample is 76% for predicting CV events. Adding UAE to FRS improved the area under the curve by 0.54% (P = 0.036; c-statistics). In the entire sample, the NRI of UAE over the FRS was not significant (P = 0.313). Given the ⁎ Continuous variables are presented as mean ± standard deviation and compared with the use of Student's t-test, in case of normal distribution. In case of skewed distribution, continuous variables are presented as median (interquartile range) and compared using the Kruskall-Wallis test. Fig. 1 . Median urinary albumin excretion (mg/24 h) by treatment and visit. Triangles refer to placebo group and circles refer to treatment group (fosinopril). Fig. 2 . A and B. Predicted Framingham Risk Score compared to Kaplan-Meier estimates of incidence of cardiovascular events in fosinopril and placebo group, divided by a UAE b50 mg/24 h and UAE ≥50 mg/24 h.
Table 2
Observed incidence of primary endpoint, divided by UAE groups. increased event rate observed in subjects with UAE ≥ 50 mg/24 h, we repeated the NRI analysis in subjects in the high UAE group (N = 167). This resulted in a reclassification of 4.6%, however not significant (P = 0.313) (see Supplementary Tables 1A and 1B) .
Discussion
Previously, the PREVEND IT trial reported on a high CV risk in subjects with elevated UAE (≥50 mg/24 h), with an event rate of almost 30% after 10 years of follow-up [10] . In this sub-analysis we compared the observed event rate in PREVEND IT with the populations' FRSestimated risk. Our results indicate that the FRS substantially underestimates CV risk of subjects with UAE ≥50 mg/24 h and that this increased risk is amenable to treatment with the ACE inhibitor fosinopril, the use of which reduced the risk to the FRS-estimated risk. Adding UAE to the FRS, using a cut point of 50 mg/24 h, furthermore increased the area under the curve and IDI in risk estimation.
The FRS is the most well-known and most widely used models for CV risk stratification. Although the FRS does not suffice for specific risk groups, for example young or low-risk patients [17] , its use for a general risk prediction for CV disease is undisputed. Still, multiple attempts have been made to improve CV risk stratification by adding variables to the FRS, like non-invasive vascular assessments [18] , coronary artery calcium score [19] , or brachial artery flow-mediated dilation [20] , and several other variables. Limited studies have been done investigating the additional value of UAE on the FRS. The group of Cao et al. showed in elderly subjects that the combination of UAE with the Framingham Risk Score improved risk stratification, over a follow-up period of 5.6 years [11] . Other studies used albumin-creatinine ratio alone, or in combination with other biomarkers to improve FRS [21, 22] .
In the current analysis, we compared the predicted 10-year CV risk to the observed event rate during follow-up. For subjects with an UAE b50 mg/24 h, the FRS proved to be very accurate. In contrast, subjects in the highest UAE quintile (≥ 50 mg/24 h) were substantially underestimated with regard to their CV risk. The addition of UAE ≥ 50 mg/24 h to the FRS increased the IDI and area under the curve significantly, implying additional value in predicting individual 10-year CV risk. This is strengthened by the observed high incidence of CV events in subjects in the highest quintile of UAE. In addition, the increased rate of observed CV events was neutralized in the group treated with fosinopril. Fosinopril-treated subjects also showed a significant decrease in UAE during the active trial period, while there was little effect of fosinopril treatment on blood pressure [13] .
We however did not find any additional value of UAE over the FRS using NRI, which can be explained by several factors. The IDI differs from the NRI in that the population is not cross-classified by fixed levels from the two prediction models. The conventional and widely used risk categories used in this analysis (b 10%; 10-20%; N 20%) might not have been suitable for assessing additional value of UAE. Also, the baseline average FRS for subjects in PREVEND IT is 12.7%, which is already considerably increased. This is due to the relative high percentage of tobacco users and an average systolic blood pressure of 129 mm Hg at baseline in PREVEND IT. The lack of additional value of UAE might be caused by the already present high baseline risk for CV disease. Finally, the NRI was performed in the total sample and the sub-group of subjects with UAE ≥ 50 mg/24 h, however irrespectively of treatment group. This could have diluted the additional value of UAE, while the subjects treated with fosinopril compared to placebo had less CV events during follow-up. Our study was unfortunately underpowered to assess the difference in added value of UAE over FRS for both treatment groups separately.
Study limitations
The study sample in this trial had a relatively low CV risk. Less than 3% of the participants were diabetic, and evidence of prior cardiac events such as myocardial infarction, bypass surgery, or heart failure was all b 1% each. In line with this, the number of cardiovascular events was low. The sample size of PREVEND IT does not allow making definite statements about the role of UAE in prediction CV risk. We used the FRS as standard method of evaluation cardiovascular risk, despite the fact that this score refers to the US population. Risk scores may be subject to bias, however the FRS is generally assumed to be an accurate score and is widely used.
Conclusions
In the subjects with elevated UAE (≥50 mg/24 h) the actual 10-year CV risk was significantly higher than predicted by FRS, and this excess risk was neutralized by fosinopril treatment. The FRS should be used carefully in subjects with increased levels of UAE, as it underestimates their CV risk.
